LENZ Therapeutics, Inc.
LENZ
$7.34
$0.050.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.99M | 19.09M | 17.50M | 5.00M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.99M | 19.09M | 17.50M | 5.00M | -- |
| Cost of Revenue | 1.49M | 418.00K | -- | -- | -- |
| Gross Profit | 19.50M | 18.67M | 17.50M | 5.00M | -- |
| SG&A Expenses | 124.99M | 91.14M | 60.86M | 39.76M | 34.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 139.33M | 110.23M | 85.40M | 66.96M | 59.45M |
| Operating Income | -118.34M | -91.14M | -67.90M | -61.96M | -59.45M |
| Income Before Tax | -108.49M | -81.63M | -58.38M | -51.90M | -47.74M |
| Income Tax Expenses | 502.00K | 502.00K | 501.00K | 501.00K | 1.00K |
| Earnings from Continuing Operations | -109.00 | -82.13 | -58.88 | -52.40 | -47.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.00M | -82.13M | -58.88M | -52.40M | -47.74M |
| EBIT | -118.34M | -91.14M | -67.90M | -61.96M | -59.45M |
| EBITDA | -117.98M | -90.85M | -67.70M | -61.87M | -59.36M |
| EPS Basic | -3.59 | -2.80 | -2.11 | -1.90 | -1.77 |
| Normalized Basic EPS | -2.24 | -1.74 | -1.31 | -1.18 | -1.14 |
| EPS Diluted | -3.59 | -2.80 | -2.11 | -1.90 | -1.77 |
| Normalized Diluted EPS | -2.24 | -1.74 | -1.31 | -1.18 | -1.14 |
| Average Basic Shares Outstanding | 119.04M | 115.22M | 111.64M | 110.27M | 107.80M |
| Average Diluted Shares Outstanding | 119.04M | 115.22M | 111.64M | 110.27M | 107.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |